Cyclic nucleotides and mitogen-activated protein kinases: Regulation of simvastatin in platelet activation

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Lee, Ye Ming ^a,b,c   Chen, Wei Fan ^c   Chou, Duen Suey ^c   Jayakumar, Thanasekaran ^c   Hou, Ssu Yu ^c   Lee, Jie Jen ^c   Hsiao, George ^c   Sheu, Joen Rong ^c  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; CALCIUM ION; COLLAGEN; CYCLIC AMP; CYCLIC NUCLEOTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE C; SIMVASTATIN; STRESS ACTIVATED PROTEIN KINASE; THROMBIN; THROMBOXANE A2; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; CYCLIC GMP; HYDROXYL RADICAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NOS3 PROTEIN, HUMAN; PHOSPHOLIPASE C GAMMA; PHOSPHOPROTEIN; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ANTICOAGULATION; ARTICLE; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; ELECTRON SPIN RESONANCE; FLOW CYTOMETRY; HUMAN; IMMUNOBLOTTING; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; BLOOD; CALCIUM SIGNALING; DRUG EFFECT; IN VITRO STUDY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CALCIUM SIGNALING; CELL ADHESION MOLECULES; COLLAGEN; CYCLIC AMP; CYCLIC GMP; HUMANS; HYDROXYL RADICAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAP KINASE SIGNALING SYSTEM; MICROFILAMENT PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NUCLEOTIDES, CYCLIC; PHOSPHOLIPASE C GAMMA; PHOSPHOPROTEINS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROTEIN KINASE C; SIGNAL TRANSDUCTION; SIMVASTATIN; THROMBOXANE A2;

EID: 77952967766     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-45     Document Type: Article

References (26)

1. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. A Notarbartolo G Davi M Averna CM Barbagallo A Ganci C Giammarresi FP La Placa C Patrono, Arterioscler Thromb Vasc Biol 1995 15 247 251 7749833
2. Current perspectives on statins. DJ Maron S Fazio MF Linton, Circulation 2000 101 207 213 10637210
3. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. A Undas KE Brummel J Musial KG Mann A Szczeklik, Circulation 2001 103 2248 2253 11342472
4. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. RS Rosenson CC Tangney, JAMA 1998 279 1643 1650 10.1001/jama.279.20.1643 9613915
5. Statins: effective antiatherosclerotic therapy. RS Blumenthal, Am Heart J 2000 139 577 583 10.1016/S0002-8703(00)90033-4 10740137
6. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin. TC Chou YF Lin WC Wu KM Chu, Br J Pharmacol 2008 153 1281 1287 10.1038/bjp.2008.19 18264124
7. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. H Osamah R Mira S Sorina K Shlomo A Michael, Br J Clin Pharmacol 1997 44 77 83 10.1046/j.1365-2125.1997.00625.x 9241100
8. 2with pravastatin therapy for hypercholesterolemia. LP Ma DN Nie SX Hsu SM Yin LZ Xu JV Nunes, J Assoc Acad Minor Phys 2002 13 23 26 11852667
9. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. JR Sheu CR Lee CH Lin G Hsiao WC Ko YC Chen MH Yen, Thromb Haemost 2000 72 617 621
10. Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. JR Sheu WC Hung CH Wu MC Ma YC Kan CH Lin MS Lin HN Luk MH Yen, Circulation 1999 99 3056 3062 10368125
11. ESR spin-trapping of a carbon-centered free radical from agonist-stimulated human platelets. DS Chou G Hsiao MY Shen YJ Tsai TF Chen JR Sheu, Free Rad Biol Med 2005 39 237 248 10.1016/j.freeradbiomed.2005.03.011 15964515
12. Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. WD Singer HA Brown PC Sternweis, Annu Rev Biochem 1997 66 475 509 10.1146/annurev.biochem.66.1.475 9242915
13. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. A Aszodi A Pfeifer M Ahmad M Glauner XH Zhou L Ny KE Anderson B Kegrel S Offermanns, EMBO J 1999 18 37 48 10.1093/emboj/18.1.37 9878048
14. Pravastatin sodium activates endothelial nitric oxide synthease independent of its cholesterol-lowering actions. WH Kaesemeyer RB Caldwell J Huang W Caldwell, J Am Coll Cardiol 1999 33 234 241 10.1016/S0735-1097(98)00514- 2 9935036
15. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. KC Huang CW Chen JC Chen WW Lin, J Biomed Sci 2003 10 396 405 10.1007/BF02256431 12824699
16. Signaling role for phospholipase C gamma 2 in platelet glycoprotein Ib alpha calcium flux and cytoskeletal reorganization. Involvement of a pathway distinct from FcR gamma chain and Fc gamma RIIA. P Mangin Y Yuan I Goncalves A Eckly M Freund JP Cazenave C Gachet SP Jackson F Lanza, J Biol Chem 2003 278 32880 32891 10.1074/jbc.M302333200 12813055
17. The aging brain, a key target for the future: the protein kinase C involvement. A Pascale M Amadio S Govoni F Battaini, Pharmacol Res 2007 55 560 569 10.1016/j.phrs.2007.04.013 17553691
18. Phospholipase C epsilon: linking second messengers and small GTPases. TD Bunney M Katan, Trends Cell Biol 2006 16 640 648 10.1016/j.tcb.2006.10.007 17085049
19. Roles of the C-terminal tyrosine residues of LAT in GPVI-induced platelet activation: insights into the mechanism of PLC gamma 2 activation. A Ragab S Severin MP Gratacap E Aguado M Malissen M Jandrot-Perrus B Malissen J Ragab-Thomas B Payrastre, Blood 2007 110 2466 2474 10.1182/blood-2007-02-075432 17579183
20. Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. F Bugaud F Nadal-Wollbold S Levy-Toledano JP Rosa M Bryckaert, Blood 1999 94 3800 3805 10572094
21. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. PE Hughes MW Renshaw M Pfaff J Forsyth VM Keivens MA Schwartz MH Ginsberg, Cell 1997 88 521 530 10.1016/S0092-8674(00) 81892-9 9038343
22. Caffeine inhibits UV-mediated NF-kappaB activation in A2058 melanoma cells: an ATM-PKCdelta-p38 MAPK-dependent mechanism. D Ravi H Muniyappa KC Das, Mol Cell Biochem 2008 308 193 200 10.1007/s11010-007-9628-x 17932622
23. 2cascade in hydroperoxide-stressed platelets. L Coulon C Calzada P Moulin E Vericel M Lagarde, Free Rad Biol Med 2003 35 616 625 10.1016/S0891-5849(03)00386-1 12957654
24. Role of cyclic nucleotide-dependent protein kinases and their common substrate VASP in the regulation of human platelets. U Walter M Eigenthaler J Geiger M Reinhard, Adv Exp Med Biol 1993 344 237 249 8209791
25. Platelet-derived nitric oxide signaling and regulation. E Gkaliagkousi J Ritter A Ferro, Circ Res 2007 101 654 662 10.1161/CIRCRESAHA.107.158410 17901370
26. 2-Adrenoceptors activate nitric oxide synthase in human platelets. LR Queen B Xu K Horinouchi I Fisher A Ferro, Circ Res 2000 87 39 44 10884370